Recombinant modified vaccinia virus Ankara-based malaria vaccines.
A safe and effective malaria vaccine is a crucial part of the roadmap to malaria elimination/eradication by the year 2050. Viral-vectored vaccines based on adenoviruses and modified vaccinia virus Ankara (MVA) expressing malaria immunogens are currently being used in heterologous prime-boost regimes in clinical trials for induction of strong antigen-specific T-cell responses and high-titer antibodies. Recombinant MVA is a safe and well-tolerated attenuated vector that has consistently shown significant boosting potential. Advances have been made in large-scale MVA manufacture as high-yield producer cell lines and high-throughput purification processes have recently been developed. This review describes the use of MVA as malaria vaccine vector in both preclinical and clinical studies in the past 5 years.
a The Jenner Institute , University of Oxford , Oxford , UK.
Sarah
S
Sebastian
a The Jenner Institute , University of Oxford , Oxford , UK.
Sarah C
SC
Gilbert
D002986:Clinical Trials as Topic; D004337:Drug Carriers / Q000302:isolation & purification*; D005822:Genetic Vectors / Q000302:isolation & purification*; D006801:Humans; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics* / Q000254:growth & development / Q000302:isolation & purification*
D004337:Drug Carriers; D017780:Malaria Vaccines; D014614:Vaccines, Synthetic
clinical trials; heterologous prime-boost; malaria; modified vaccinia virus Ankara (MVA); plasmodium; vaccine